Nctid:
NCT00001184
Payload:
{"FullStudy"=>{"Rank"=>498160, "Study"=>{"DerivedSection"=>{"MiscInfoModule"=>{"VersionHolder"=>"June 24, 2024"}, "ConditionBrowseModule"=>{"ConditionMeshList"=>{"ConditionMesh"=>[{"ConditionMeshId"=>"D000003092", "ConditionMeshTerm"=>"Colitis"}, {"ConditionMeshId"=>"D000003093", "ConditionMeshTerm"=>"Colitis, Ulcerative"}, {"ConditionMeshId"=>"D000007410", "ConditionMeshTerm"=>"Intestinal Diseases"}, {"ConditionMeshId"=>"D000015212", "ConditionMeshTerm"=>"Inflammatory Bowel Diseases"}, {"ConditionMeshId"=>"D000014456", "ConditionMeshTerm"=>"Ulcer"}]}, "ConditionAncestorList"=>{"ConditionAncestor"=>[{"ConditionAncestorId"=>"D000005759", "ConditionAncestorTerm"=>"Gastroenteritis"}, {"ConditionAncestorId"=>"D000005767", "ConditionAncestorTerm"=>"Gastrointestinal Diseases"}, {"ConditionAncestorId"=>"D000004066", "ConditionAncestorTerm"=>"Digestive System Diseases"}, {"ConditionAncestorId"=>"D000003108", "ConditionAncestorTerm"=>"Colonic Diseases"}, {"ConditionAncestorId"=>"D000010335", "ConditionAncestorTerm"=>"Pathologic Processes"}]}, "ConditionBrowseLeafList"=>{"ConditionBrowseLeaf"=>[{"ConditionBrowseLeafId"=>"M10444", "ConditionBrowseLeafName"=>"Intestinal Diseases", "ConditionBrowseLeafAsFound"=>"Bowel Disease", "ConditionBrowseLeafRelevance"=>"high"}, {"ConditionBrowseLeafId"=>"M17917", "ConditionBrowseLeafName"=>"Inflammatory Bowel Diseases", "ConditionBrowseLeafAsFound"=>"Inflammatory Bowel Disease", "ConditionBrowseLeafRelevance"=>"high"}, {"ConditionBrowseLeafId"=>"M6320", "ConditionBrowseLeafName"=>"Colitis", "ConditionBrowseLeafAsFound"=>"Colitis", "ConditionBrowseLeafRelevance"=>"high"}, {"ConditionBrowseLeafId"=>"M6321", "ConditionBrowseLeafName"=>"Colitis, Ulcerative", "ConditionBrowseLeafAsFound"=>"Ulcerative Colitis", "ConditionBrowseLeafRelevance"=>"high"}, {"ConditionBrowseLeafId"=>"M17206", "ConditionBrowseLeafName"=>"Ulcer", "ConditionBrowseLeafAsFound"=>"Ulcerative", "ConditionBrowseLeafRelevance"=>"high"}, {"ConditionBrowseLeafId"=>"M6638", "ConditionBrowseLeafName"=>"Crohn Disease", "ConditionBrowseLeafRelevance"=>"low"}, {"ConditionBrowseLeafId"=>"M8875", "ConditionBrowseLeafName"=>"Gastroenteritis", "ConditionBrowseLeafRelevance"=>"low"}, {"ConditionBrowseLeafId"=>"M7255", "ConditionBrowseLeafName"=>"Digestive System Diseases", "ConditionBrowseLeafRelevance"=>"low"}, {"ConditionBrowseLeafId"=>"M8883", "ConditionBrowseLeafName"=>"Gastrointestinal Diseases", "ConditionBrowseLeafRelevance"=>"low"}, {"ConditionBrowseLeafId"=>"M6336", "ConditionBrowseLeafName"=>"Colonic Diseases", "ConditionBrowseLeafRelevance"=>"low"}]}, "ConditionBrowseBranchList"=>{"ConditionBrowseBranch"=>[{"ConditionBrowseBranchName"=>"Digestive System Diseases", "ConditionBrowseBranchAbbrev"=>"BC06"}, {"ConditionBrowseBranchName"=>"All Conditions", "ConditionBrowseBranchAbbrev"=>"All"}, {"ConditionBrowseBranchName"=>"Symptoms and General Pathology", "ConditionBrowseBranchAbbrev"=>"BC23"}]}}}, "ProtocolSection"=>{"DesignModule"=>{"StudyType"=>"Observational", "DesignInfo"=>{"DesignTimePerspectiveList"=>{"DesignTimePerspective"=>["Prospective"]}, "DesignObservationalModelList"=>{"DesignObservationalModel"=>["Cohort"]}}, "EnrollmentInfo"=>{"EnrollmentType"=>"Anticipated", "EnrollmentCount"=>"1000"}}, "StatusModule"=>{"OverallStatus"=>"Recruiting", "StartDateStruct"=>{"StartDate"=>"August 7, 1998", "StartDateType"=>"Actual"}, "ExpandedAccessInfo"=>{"HasExpandedAccess"=>"No"}, "StatusVerifiedDate"=>"May 30, 2024", "LastUpdateSubmitDate"=>"June 19, 2024", "StudyFirstSubmitDate"=>"November 3, 1999", "StudyFirstSubmitQCDate"=>"November 3, 1999", "LastUpdatePostDateStruct"=>{"LastUpdatePostDate"=>"June 21, 2024", "LastUpdatePostDateType"=>"Actual"}, "StudyFirstPostDateStruct"=>{"StudyFirstPostDate"=>"November 4, 1999", "StudyFirstPostDateType"=>"Estimate"}}, "OutcomesModule"=>{"PrimaryOutcomeList"=>{"PrimaryOutcome"=>[{"PrimaryOutcomeMeasure"=>"To identify the molecular abnormalities that result in inflammatory bowel diseases and develop novel therapies based on these discoveries.", "PrimaryOutcomeTimeFrame"=>"at close of study", "PrimaryOutcomeDescription"=>"observational"}]}}, "OversightModule"=>{"IsFDARegulatedDrug"=>"No", "IsFDARegulatedDevice"=>"No"}, "ConditionsModule"=>{"KeywordList"=>{"Keyword"=>["CGD related IBD", "IBD Hermansky-Pudlak Syndrom", "Natural History"]}, "ConditionList"=>{"Condition"=>["Inflammatory Bowel Disease", "Ulcerative Colitis", "Chrohn's Disease"]}}, "ReferencesModule"=>{"SeeAlsoLinkList"=>{"SeeAlsoLink"=>[{"SeeAlsoLinkURL"=>"https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_1982-I-0183.html", "SeeAlsoLinkLabel"=>"NIH Clinical Center Detailed Web Page"}]}}, "DescriptionModule"=>{"BriefSummary"=>"This study will investigate in patients with Crohn s disease and ulcerative colitis how the body s immune system controls inflammation in the gastrointestinal tract (stomach and intestines)-specifically, how lymphocytes (a type of white blood cell) function in inflammatory responses. This protocol does not involve any experimental treatments.\n\nPatients between the ages of 0 and 75 years of age with Crohn s disease or ulcerative colitis or symptoms of inflammatory bowel disease may be eligible for this study. Screening tests may include the following: medical history and physical examination, routine blood tests, examination of stool specimens, X-rays such as barium enema or upper GI series, proctosigmoidoscopy, colonoscopy, gastroduodenoscopy, and small bowel biopsy.\n\nParticipants will receive medical treatment according to the best generally accepted measures for treating Crohn s disease or ulcerative colitis. This may include anti-inflammatory drugs, immunosuppressive drugs, and antibiotics to treat infections. A surgical consultation may be recommended for patients whose disease does not respond to medical treatment. If surgery to remove intestinal tissue is recommended, a qualified gastrointestinal surgeon will perform the procedure.\n\nIn addition, participants may undergo the following procedures:\n\nBlood drawing - No more than 450 milliliters (30 tablespoons, or 15 ounces) of blood will be taken from adults over a 6-week period. A maximum of 7 ml (1/2 tablespoon) of blood per kilogram (2.2. pounds) of body weight will be obtained from children within the same time period, with no more than 3 ml/kg taken at any one time.\nLeukapheresis - This procedure is done to collect large quantities of white blood cells. Whole blood is collected through a needle in an arm vein, similar to donating blood. The blood is circulated through a machine that separates it into its components, and the white cells are removed. The rest of the blood is returned to the body, either through the same needle or through another needle in the other arm.\nIntestinal biopsies - Intestinal tissue will be obtained during colonoscopy with intestinal biopsy in patients who require this procedure as part of their standard medical care. Patients are given a sedative to reduce anxiety, but are conscious during the procedure. A flexible tube is inserted into the rectum and large intestine, allowing the physician to see the intestinal mucosa. At various places, small pieces of tissue are plucked out.", "DetailedDescription"=>"This natural history protocol provides for the evaluation of patients with idiopathic inflammatory bowel diseases (ulcerative colitis, Crohn's disease, IBD associated with immunodeficiency and genetic diseases such as chronic granulomatous disease and Hermansky-Pudlak syndrome, and additional undefined inflammatory conditions of the gut) either on an inpatient or outpatient basis. The purpose of this protocol is to assess the extent and activity of the disease in such patients, conduct immunologic studies of lymphocyte and antigen-presenting cells derived from peripheral blood and tissues, administer and monitor treatments, and study the genetic risk factors for these diseases. This study will also be used to provide a mechanism for procurement of intestinal samples obtained at sites outside the NIH at the time of medically indicated surgical or endoscopic procedures from patients with IBD. In addition, it will allow for the procurement (send-in) of blood for both immunological studies as well as DNA preparation as more IBD susceptibility genes are discovered and we further our work on association of genetic polymorphisms/mutations with the phenotype and immune abnormalities observed in our IBD patients. This protocol will also allow for the procurement of blood and tissue samples from healthy volunteers (without IBD) here at the NIH to use as a control group in comparison to the immunologic and genetic data we obtain from the IBD patients that are enrolled. The immediate aims of these studies are to define the immunologic abnormalities present and to identify genetic susceptibility factors in patients with these diseases. The long-term goal of this protocol is to identify specific targets for development of novel therapeutics for inflammatory bowel diseases."}, "EligibilityModule"=>{"Gender"=>"All", "MaximumAge"=>"75 years", "StdAgeList"=>{"StdAge"=>["Child", "Adult", "Older Adult"]}, "SamplingMethod"=>"Non-Probability Sample", "StudyPopulation"=>"Clinical", "HealthyVolunteers"=>"Accepts Healthy Volunteers", "EligibilityCriteria"=>"INCLUSION CRITERIA:\n\nPatients with a verifiable diagnosis of Crohn s disease, ulcerative colitis, or IBD known to be associated with a co-existing condition and which is supported by characteristic clinical features, radiographic or endoscopic findings, or consistent histopathologic mucosal\n\nchanges OR\n\nPatients with clinical features consistent with an unclassified inflammatory bowel disease and histologic evidence of inflammation of the intestine OR\n\nPatients with any clinical features consistent with inflammatory bowel disease (intestinal inflammation), including but not limited to abdominal pain, fistulae, weight loss, diarrhea, hematochezia or melena or suggestive extra-intestinal symptoms (pyoderma, erythema\n\nnodosum, axial and articular arthralgias, uveitis, fatigue, fever), in which a diagnosis has not been verified. OR\n\nPatients who have a defined genetic syndrome linked to inflammatory bowel disease risk with or without symptoms or findings consistent with IBD\n\nAll subjects to be enrolled will be between ages 0-75 (Participants coming to the NIH Clinical Center must meet age and weight requirements of the clinical center, but > 18 must years old for patients without IBD and may be as young as 0-2 years old for mail-in\n\nsamples).\n\nTo participate in the research biopsies during endoscopy, subjects must have the following lab values within two weeks of the procedure:\n\nHematocrit greater than or equal to 30%\nPlatelet count greater than 100,000\nPT INR less than or equal to 1.3 or PTT prolonged by less than or equal to 3 seconds\nAbility to consent to the protocol on their own.\n\nINCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:\n\nMust be willing to undergo blood draw and/or upper endoscopy and colonoscopy with biopsy to obtain material for research purposes.\nMust be greater than or equal to 18 years old.\nMust be willing to submit samples for storage.\n\nINCLUSION OF EMPLOYEES IN THE NIH INTRAMURAL STUDIES:\n\nNIH employees and members of their immediate families may participate in this protocol. We will follow the Guidelines for the Inclusion of Employees in NIH Research Studies and will give each employee a copy of the NIH information sheet on Employee Research Participation.\n\nFor NIH employees:\n\nNeither participation nor refusal to participate will have an effect, either beneficial or adverse, on the participant s employment or work situation.\nThe NIH information sheet regarding NIH employee research participation will be distributed to all potential subjects who are NIH employees.\nThe employee subject s privacy and confidentiality will be preserved in accordance with NIH Clinical Center and NIAID policies, which define the scope and limitations of the protections.\nFor NIH employee subjects, consent will be obtained by an individual independent of the employee s team. Those in a supervisory position to any employee and co-workers of the employee will not obtain consent. The protocol study staff will be trained annually on obtaining potentially sensitive and private information from co-workers or subordinates. This training will be reinforced as needed, at weekly team meetings.\n\nEXCLUSION CRITERIA:\n\nFailure to meet the inclusion criteria.\nAny medical, psychiatric, or social conditions which, in the opinion of the investigators, would make participation in this protocol not in the best interest of the subject.\n\nEXCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:\n\nHistory of inflammatory bowel disease.\nAcute systemic or intestinal infection requiring antibiotics\nAny condition that, in the investigator s opinion, places the patient at undue risk by participating in the study."}, "IdentificationModule"=>{"NCTId"=>"NCT00001184", "BriefTitle"=>"Immune Regulation in Ulcerative Colitis or Crohn s Disease", "Organization"=>{"OrgClass"=>"NIH", "OrgFullName"=>"National Institutes of Health Clinical Center (CC)"}, "OfficialTitle"=>"A Natural History Study of the Immune Regulation of Idiopathic Inflammatory Bowel Diseases: Crohn's Disease, Ulcerative Colitis, and Other Inflammatory Conditions of the Gut", "OrgStudyIdInfo"=>{"OrgStudyId"=>"820183"}, "SecondaryIdInfoList"=>{"SecondaryIdInfo"=>[{"SecondaryId"=>"82-I-0183"}]}}, "ArmsInterventionsModule"=>{"ArmGroupList"=>{"ArmGroup"=>[{"ArmGroupLabel"=>"1", "ArmGroupDescription"=>"Patients between the ages of 0 and 75 years of age with Crohn s disease or ulcerative colitis or symptoms of inflammatory bowel disease may be eligible for this study."}]}}, "ContactsLocationsModule"=>{"LocationList"=>{"Location"=>[{"LocationZip"=>"20892", "LocationCity"=>"Bethesda", "LocationState"=>"Maryland", "LocationStatus"=>"Recruiting", "LocationCountry"=>"United States", "LocationFacility"=>"National Institutes of Health Clinical Center"}]}, "CentralContactList"=>{"CentralContact"=>[{"CentralContactName"=>"Sandra M Maxwell, R.N.", "CentralContactRole"=>"Contact", "CentralContactEMail"=>"maxwells@mail.nih.gov", "CentralContactPhone"=>"(240) 627-3078"}, {"CentralContactName"=>"Ivan J Fuss, M.D.", "CentralContactRole"=>"Contact", "CentralContactEMail"=>"ifuss@niaid.nih.gov", "CentralContactPhone"=>"(301) 761-7091"}]}, "OverallOfficialList"=>{"OverallOfficial"=>[{"OverallOfficialName"=>"Ivan J Fuss, M.D.", "OverallOfficialRole"=>"Principal Investigator", "OverallOfficialAffiliation"=>"National Institute of Allergy and Infectious Diseases (NIAID)"}]}}, "SponsorCollaboratorsModule"=>{"LeadSponsor"=>{"LeadSponsorName"=>"National Institute of Allergy and Infectious Diseases (NIAID)", "LeadSponsorClass"=>"NIH"}, "ResponsibleParty"=>{"ResponsiblePartyType"=>"Sponsor"}}}}}}
